Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Venetoclax og azacitidin til behandling af akut myeloid leukæmi efter transplantation

30. september 2026 opdateret af: M.D. Anderson Cancer Center

Et fase II-studie af Venetoclax i kombination med azacitidin i post-transplantationsmiljøet for AML, T-celleleukæmi og blandet fænotype akut leukæmi

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

1. To determine relapse-free survival after the use of venetoclax in combination with azacitidine given as maintenance therapy or for eradication of minimal residual disease in patients with high risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT).

SECONDARY OBJECTIVES:

  1. To determine the safety and toxicity of venetoclax in combination with azacitidine (type, frequency, severity of adverse events [AEs] and relationship of AEs to venetoclax)
  2. To determine response duration, overall survival.
  3. To determine Incidence of acute and chronic graft versus host disease (GVHD)
  4. To perform matched pairs analysis to obtain bias corrected treatment comparisons of Venetoclax + Vidaza (V+V) to standard therapy in AML patients with no evidence of disease (AML D-) subgroup.

EXPLORATORY OBJECTIVE:

1. To investigate possible relationships between baseline protein and gene expression signatures/mutation profile and BH3 profiling in predicting relapse-free survival time to the combination. This exploratory analysis will be done for the data from the entire study, accounting for the noted biological variables covariates, as well as disease status and whether or not the patient had AML, by fitting a Bayesian time-to-event regression model with RFS the outcome variable.

OUTLINE:

Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine subcutaneously (SC) on days 1-5 and venetoclax orally (PO) once daily (QD) on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

100

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • M D Anderson Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants 18 to 75 years of age.

  2. English and non-English speaking patients are eligible.

  3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.

    1. AML if they had at least one of the following disease characteristics:

      • Therapy related AML.
      • Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML (see Appendix A.).
      • Primary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis.
      • Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT.
      • Presence of active disease defined as bone marrow blast count >5% at the time of HSCT.
      • Participants transplanted beyond first remission. OR
    2. Biphenotypic or bilineage leukemia (including a myeloid component) OR mixed phenotype acute leukemia (MPAL) OR

    3. Participants with acute lymphoblastic leukemia; B cell or T cell in original.

  4. Participants in morphological remission with no detectable minimal residual disase (MRD) after transplant

  5. Participants who are in remission with no detectable minimal residual disease (MRD) after allogeneic stem cell transplant should have:

    1. Adequate engraftment within 14 days prior to starting study drug:
    2. Absolute neutrophil count (ANC) >/= 1.0 x 109/L without daily use of myeloid growth factor (G-CSF) for at least 7 days; and,
    3. Platelet >/= 30 x 109/L without platelet transfusion within 1 week
    4. Be able to start the drug therapy between 42 to 100 days following HSCT.
  6. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:

    1. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR

    2. Myeloablative regimens including:

      • Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR
      • Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
  7. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.

  8. ECOG performance status of 0, 1, or 2.

  9. Serum creatinine </=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation*

  10. Serum bilirubin </= 1.5 x upper limit of normal (ULN).

  11. Aspartate transaminase (AST) or alanine transaminase (ALT) </= 2.5 x ULN.

  12. Alkaline phosphatase </= 2.5 x UL.

  13. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

  14. Negative serum or urine pregnancy test for women with reproductive potential. The only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile. 3.1.2. For cohort #3 and cohort #4 patients (MRD positive cohort):

  1. Participants 18 to 75 years of age.

  2. English and non-English speaking patients are eligible.

  3. Disease diagnosis with one of the hematological malignancies listed below and who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow. a. AML OR b. Biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) OR c. Participants with acute lymphoblastic leukemia; B cell or T cell in original.

  4. Persistence or reappearance of MRD by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.

    1. When MRD is detected by flow cytometry, disease level at or above the sensitivity level of the test will be required. • MRD level at or above 0.01% for B cell ALL and T cell ALL.

      • MRD level at or above 0.1% for AML and mixed phenotype acute leukemia.

    2. When MRD is detected by cytogenetics, disease level at or above the sensitivity level of the test will be required.

      • The limited of detection is about 0.25% for males and 0.44% for females.

    3. When MRD is detected by molecular testing, disease level at or above the sensitivity level of the test will be required. • The limited of detection is 0.01%

  5. Use of one of the conditioning regimens as part of allogeneic stem cell transplant listed below:

    a. Reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan OR b. Myeloablative regimens including:

    • Busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen OR

    • Total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.
  6. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.

  7. ECOG performance status of 0, 1, or 2.

  8. Serum creatinine </=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation*

  9. Serum bilirubin </= 1.5 x upper limit of normal (ULN).

  10. Aspartate transaminase (AST) or alanine transaminase (ALT) </= 2.5 x ULN.

  11. Alkaline phosphatase </= 2.5 x UL.

  12. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

  13. Negative serum or urine pregnancy test for women with reproductive potential. The only participants who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile.

Exclusion Criteria:

  1. Active acute GVHD grade II or higher.

  2. Active chronic GVHD that is extensive (see Appendix C.).

  3. Uncontrolled GVHD (see Appendix C.).

  4. Concurrent use of systemic immune suppressive other than calcineurin inhibitors, sirolimus and steroids

  5. Active uncontrolled systemic fungal, bacterial or viral infection.

  6. Active bleeding.

  7. Symptomatic or uncontrolled arrhythmias.

  8. Significant active cardiac disease within the previous 6 months, including:

    1. New York Heart Association (NYHA) class III or IV congestive heart failure see Appendix C.).

    Unstable angina or angina requiring surgical or medical intervention, and/or b. Myocardial infarction.

  9. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).

  10. Prior history of malignancies, other than leukemia, unless the subject has been free of the disease for >/= 1 year. However, participants with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast;
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system).
  11. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment (azacitidine, venetoclax)

Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Given PO

Andre navne:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclyxto

Given SC

Andre navne:
  • 5 AZC
  • 5-AC
  • 5-Azacytidin
  • 5-AZC
  • Azacytidin
  • Azacytidin, 5-
  • Ladakamycin
  • Mylosar
  • U-18496
  • Vidaza
  • Onureg

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Relapse-free survival (RFS) time
Tidsramme: From the date of first administration of venetoclax + azacitidine (vidaza) (V+V), assessed up to 60 days after last V+V dose

Summary statistics for RFS time will be computed for all patients and within each (disease status, disease type) subgroup. RFS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.

From the date of first administration of venetoclax + azacitidine (vidaza) (V+V), assessed up to 60 days after last V+V dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall survival (OS) time
Tidsramme: Up to 60 days after last V+V dose

Summary statistics for OS time will be computed for all patients and within each (disease status, disease type) subgroup. OS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.

Up to 60 days after last V+V dose
Incidence of severe (grade 3 or 4) infection
Tidsramme: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Graft-versus-host disease
Tidsramme: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Incidence of other inter-current adverse events during follow up
Tidsramme: Up to 60 days after last V+V dose

Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Up to 60 days after last V+V dose
Non-relapse mortality
Tidsramme: Within 90 days from the start of V+V treatment

Defined as death from any cause, within 90 days from the start of V+V treatment that is not preceded by disease recurrence. Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.

Within 90 days from the start of V+V treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Betul Oran, M.D. Anderson Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. maj 2020

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

14. oktober 2019

Først indsendt, der opfyldte QC-kriterier

14. oktober 2019

Først opslået (Faktiske)

16. oktober 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner